GABAergic control of the activity of the central nucleus of the amygdala in low- and high-anxiety rats. 2015

Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
Department of Neurochemistry, Institute of Psychiatry and Neurology, 9 Sobieskiego Street, 02-957 Warsaw, Poland. Electronic address: skorzews@ipin.edu.pl.

The aim of this study was to examine the role of GABAergic neurotransmission in amygdala nuclei in low- (LR) and high-anxiety (HR) rats after repeated corticosterone administration and acute injection of the benzodiazepine midazolam. The animals were divided into LR and HR groups based on the duration of their conditioned freezing in a contextual fear test (CFT). Repeated daily administration of corticosterone (20 mg/kg s.c.) for 21 injections increased anxiety-like behavior in the open field and reduced body weight in both the LR and HR groups. These effects of corticosterone administration were more pronounced in the HR group. Moreover, in the HR group, chronic corticosterone administration increased the duration of freezing in the CFT test compared with the appropriate control group and treated LR rats. The behavioral effects in HR rats were accompanied by an increase in the expression of c-Fos in the lateral (LA) and central (CeA) nuclei of the amygdala and by a decrease in GABA-A alpha-2 subunit density in the CeA. Acute midazolam administration significantly attenuated the neophobia and conditioned fear responses, decreased c-Fos expression in the LA and CeA, and increased alpha-2 subunit density in the CeA only in the HR group. These studies have shown that HR rats are more susceptible to the anxiogenic effects of chronic corticosterone administration, which are associated with the attenuation of GABAergic control over the amygdala output that controls emotional responses. The current data may increase understanding of the neurobiological mechanisms responsible for individual differences in the psychopathological processes induced by repeated administration of high doses of glucocorticoids or by elevated levels of these hormones, which are associated with chronic stress and affective pathology.

UI MeSH Term Description Entries
D007206 Individuality Those psychological characteristics which differentiate individuals from one another. Individual Differences,Difference, Individual,Differences, Individual,Individual Difference
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D011963 Receptors, GABA-A Cell surface proteins which bind GAMMA-AMINOBUTYRIC ACID and contain an integral membrane chloride channel. Each receptor is assembled as a pentamer from a pool of at least 19 different possible subunits. The receptors belong to a superfamily that share a common CYSTEINE loop. Benzodiazepine-Gaba Receptors,GABA-A Receptors,Receptors, Benzodiazepine,Receptors, Benzodiazepine-GABA,Receptors, Diazepam,Receptors, GABA-Benzodiazepine,Receptors, Muscimol,Benzodiazepine Receptor,Benzodiazepine Receptors,Benzodiazepine-GABA Receptor,Diazepam Receptor,Diazepam Receptors,GABA(A) Receptor,GABA-A Receptor,GABA-A Receptor alpha Subunit,GABA-A Receptor beta Subunit,GABA-A Receptor delta Subunit,GABA-A Receptor epsilon Subunit,GABA-A Receptor gamma Subunit,GABA-A Receptor rho Subunit,GABA-Benzodiazepine Receptor,GABA-Benzodiazepine Receptors,Muscimol Receptor,Muscimol Receptors,delta Subunit, GABA-A Receptor,epsilon Subunit, GABA-A Receptor,gamma-Aminobutyric Acid Subtype A Receptors,Benzodiazepine GABA Receptor,Benzodiazepine Gaba Receptors,GABA A Receptor,GABA A Receptor alpha Subunit,GABA A Receptor beta Subunit,GABA A Receptor delta Subunit,GABA A Receptor epsilon Subunit,GABA A Receptor gamma Subunit,GABA A Receptor rho Subunit,GABA A Receptors,GABA Benzodiazepine Receptor,GABA Benzodiazepine Receptors,Receptor, Benzodiazepine,Receptor, Benzodiazepine-GABA,Receptor, Diazepam,Receptor, GABA-A,Receptor, GABA-Benzodiazepine,Receptor, Muscimol,Receptors, Benzodiazepine GABA,Receptors, GABA A,Receptors, GABA Benzodiazepine,delta Subunit, GABA A Receptor,epsilon Subunit, GABA A Receptor,gamma Aminobutyric Acid Subtype A Receptors
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005239 Fear The affective response to an actual current external danger which subsides with the elimination of the threatening condition. Threat Cues,Threat Sensitivity,Cue, Threat,Fears,Sensitivity, Threat,Threat Cue,Threat Sensitivities
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001008 Anxiety Disorders Persistent and disabling ANXIETY. Anxiety Neuroses,Anxiety States, Neurotic,Neuroses, Anxiety,Anxiety Disorder,Anxiety State, Neurotic,Disorder, Anxiety,Disorders, Anxiety,Neurotic Anxiety State,Neurotic Anxiety States,State, Neurotic Anxiety,States, Neurotic Anxiety

Related Publications

Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
June 2014, Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
August 2010, Nan fang yi ke da xue xue bao = Journal of Southern Medical University,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
November 2002, Brain research,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
January 2019, The Journal of pharmacology and experimental therapeutics,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
November 2011, Brain research,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
August 2007, Stress (Amsterdam, Netherlands),
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
January 2000, Physiology & behavior,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
February 1988, Behavioral neuroscience,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
April 2013, Neuropharmacology,
Anna Skórzewska, and Małgorzata Lehner, and Aleksandra Wisłowska-Stanek, and Danuta Turzyńska, and Alicja Sobolewska, and Paweł Krząścik, and Adam Płaźnik
April 2022, Molecular psychiatry,
Copied contents to your clipboard!